NDLI: Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma

Content Provider	Springer Nature Link
Author	Theurer, Julie A. Stecho, William Yoo, John Kwan, Keith Wehrli, Bret Harry, Vimla Black, Morgan Pinto, Nicole Winquist, Eric Palma, David Richter, Suzanne Barrett, John W. Danielle MacNeil, S. Fung, Kevin Howlett, Christopher J. Nichols, Anthony C.
Copyright Year	2015
Abstract	PIK3CA is the only frequently-mutated, directly druggable oncogene in head and neck squamous cell carcinoma (HNSCC). However, it is unclear if a molecularly-driven intervention trial can be launched successfully, particularly within a single-institution setting secondary to the infrastructure necessary for mutation detection, mutation prevalence, and patient willingness to participate. This study aimed to evaluate 1) local frequency of PIK3CA activating mutations in HNSCC, 2) timeliness of our mutation-profiling clinical pathway, and 3) patients’ willingness to enroll in a novel neoadjuvant drug trial. Tissue biopsies of 25 consecutive cases of HNSCC were tested for activating PIK3CA mutations at three mutational hotspots by real-time polymerase chain reaction. Mutations prevalence and number of working days accrued in determining PIK3CA mutational status were calculated. In addition, 30 HNSCC patients were surveyed prospectively regarding their willingness to participate in a hypothetical drug trial. Survey data were summarized descriptively. 4 of 25 (16 %) tumors harbored a PIK3CA activating mutation, including one at codon E542K, two at codon E545K/D, and one at codon H1047R. On average, this result was obtained in approximately 15 working days (range, 9–24 working days). The majority of patients surveyed (70 %) indicated their willingness to participate in a targeted PIK3CA trial. This study provides evidence that within a single institution, PIK3CA activating mutations can be detected with expected frequency, with sufficient timeliness and sufficient patient interest to mount a targeted intervention trial that may lead to improved tumor response in selected HNSCC patients.
Starting Page	35
Ending Page	40
Page Count	6
File Format	PDF
ISSN	12194956
Journal	Pathology & Oncology Research
Volume Number	22
Issue Number	1
e-ISSN	15322807
Language	English
Publisher	Springer Netherlands
Publisher Date	2015-08-14
Publisher Place	Dordrecht
Access Restriction	Subscribed
Subject Keyword	PIK3CA Targeted therapeutics Biomarkers Head and neck squamous cell carcinoma Feasibility study Cancer Research Oncology Pathology Immunology Biomedicine general
Content Type	Text
Resource Type	Article
Subject	Cancer Research Pathology and Forensic Medicine Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

The Prognostic Role of Claudins in Head and Neck Squamous Cell Carcinomas

MUC1 mucin and carbohydrate associated antigens as tumor markers in head and neck squamous cell carcinoma

Frequency of PIK3CA mutations in different subsites of head and neck squamous cell carcinoma in southern Thailand.

Association of α$_{1}$ acidic glycoprotein and squamous cell carcinoma of the head and neck

Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.

Low Frequency of PIK3CA Gene Mutations in Hepatocellular Carcinoma in Chinese Population

Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma

Correlations Between Prognosis and Regional Biomarker Profiles in Head and Neck Squamous Cell Carcinomas

Integration of biomarkers including molecular targeted therapies in head and neck cancer.

Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma

Similar Documents

The Prognostic Role of Claudins in Head and Neck Squamous Cell Carcinomas

MUC1 mucin and carbohydrate associated antigens as tumor markers in head and neck squamous cell carcinoma

Frequency of PIK3CA mutations in different subsites of head and neck squamous cell carcinoma in southern Thailand.

Association of α$_{1}$ acidic glycoprotein and squamous cell carcinoma of the head and neck

Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.

Low Frequency of PIK3CA Gene Mutations in Hepatocellular Carcinoma in Chinese Population

Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma

Correlations Between Prognosis and Regional Biomarker Profiles in Head and Neck Squamous Cell Carcinomas

Integration of biomarkers including molecular targeted therapies in head and neck cancer.

Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma